Latest news

Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN

Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284

GenePOC announces FDA clearance for revogene™ instrument and its GBS LB test

Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen

BC Platforms Closes USD $10 million Series B Financing led by Debiopharm and Tesi to accelerate knowledge platform development

Debiopharm International uses cutting-edge ClinTrial App mobile application from ClinOne in clinical study

Debiopharm International SA Appeals to the Supreme Court regarding Towa Pharmaceutical Co., Ltd. case

Debiopharm Innovation Fund: the New Name and Investment Strategy of Debiopharm Diagnostics

Debiopharm Strategic Fund announces FDA clearance of Portfolio Company Immunexpress’ first Test